Beurs.nl monitor iconMarkt Monitor
  • AEX 0,00 839,29 0,00%
  • DE40 +580,73 20.954,83 +2,85%
  • US500^ -8,81 5.399,52 -0,16%
  • US30^ -64,50 40.492,30 -0,16%
  • EUR/USD +0,00 1,1355 +0,01%
  • WTI 0,00 61,67 0,00%
  • Gold spot +12,26 3.221,79 +0,38%

Draka Holding Terug naar discussie overzicht

trading update 12 nov 2009

2 Posts
| Omlaag ↓
  1. [verwijderd] 12 november 2009 08:16
    Draka: nettowinst 40-45 miljoen in 200912 nov 2009, 08:03 uur

    AMSTERDAM (AFN) - Kabelproducent Draka verwacht dit jaar een operationeel resultaat te boeken van 74 tot 79 miljoen euro. De nettowinst zal uitkomen op 40-45 miljoen euro, aldus Draka donderdag.

    Draka zag de volumes met 17,4 procent dalen in het afgelopen kwartaal. Het ebitda-resultaat komt dit jaar uit op 134 tot 139 miljoen euro, tegen 202,5 miljoen in 2008.

    De marktomstandigheden zijn over het algemeen aan het stabiliseren na een moeilijk eerste helft, aldus Draka donderdag. ,,We verwachten in 2010 de effecten te merken van de overheidsstimuleringsmaatregelen.''

    Op schema

    De lopende reorganisatie ligt op schema, aldus Draka. Van de verwachte 60 miljoen euro op jaarbasis aan kostenbesparingen vanaf 2010 denkt het concern in 2009 30 miljoen euro te realiseren.

    Draka verwacht de schulden eind dit jaar met 220 miljoen te kunnen verlagen ten opzichte van eind vorig jaar dankzij een positieve kasstroom en de recente opbrengst uit de aandelenemissie.

  2. [verwijderd] 12 november 2009 09:00
    Hierbij het gehele persbericht van Draka zelf:

    Published: 07:30 12.11.2009 GMT+1 /HUGIN /Source: Draka Holding NV /AEX: DRAK /ISIN: NL0000347813

    Draka Holding N.V.: Trading Update 2009

    Operating result of € 74-79 million and net result of € 40-45 million expected in 2009
    (both excluding non-recurring items)

    Sustained focus on cost reductions and cash flow generating capacity


    Volume down 17.4% in the period July-October 2009, stable relative to H1 2009. Lower volume mainly driven by lower construction volumes in Europe and reduced demand for copper communication cable and elevator cable. Demand in the automotive sector is recovering relative to H1 2009 in response to government measures.
    EBITDA[1] of € 134-139 million projected for 2009 (2008: € 202.5 million).
    Operating result[1] of € 74-79 million expected for 2009 (2008: € 142.0 million).
    Result for the year[1] of € 40-45 million expected (2008: € 83.5 million).
    Market conditions in general are stabilising after a difficult H1 2009. Instead of 2009, the effect of government stimulus measures could be felt in 2010, particularly in the renewable energy and infrastructure sectors.
    Cost-saving programmes that have already been implemented are on track. Total annual cost savings estimated at € 60 million from 2010 onwards, of which about € 30 million will be realised in 2009.
    Operating working capital as a percentage of revenue expected to be 14-15%, below the target bandwidth of 16-18% (2008: 15.0%).
    Net debt will be around € 220 million lower compared with year-end 2008 (€ 519 million), due to positive cash flow trend, the recent share issue and partial use of the standby arrangement.
    Amsterdam, 12 November 2009 - This trading update for 2009 is issued by Draka Holding N.V., one of the world's leading producers of low-voltage cable, cable for OEMs and communication cable, ahead of the publication of its full-year figures on Monday, 22 February 2010 (before start of trading).

    Commenting on the projected results for 2009, Frank Dorjee, CFO of Draka Holding N.V, said: 'The global cable market has faced a significant fall in demand in 2009. The consequences have been mitigated as far as possible by actions we took at an early stage to intensify our focus on customers, costs and cash. Given the circumstances, we expect Draka to post a satisfactory result for 2009, excluding non-recurring items.

    Despite stabilising demand in many of our markets since the second quarter, the economic recovery - and hence the recovery in end-user demand - is fragile. Draka will therefore continue to focus on achieving additional cost savings, by further streamlining the organisation and reducing overhead, and increasing the group's cash flow generating capacity, by maintaining capital discipline. We shall be well placed to derive maximum benefit when Draka's end-user markets recover.'

    [1] Excluding non-recurring items. Gross non-recurring items in 2009 are expected to be around € 60 million negative (2008: € 46.7 million negative).

    Groet,
    Gert
2 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.172
AB InBev 2 5.546
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.522
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.893
Aedifica 3 927
Aegon 3.258 323.215
AFC Ajax 538 7.093
Affimed NV 2 6.307
ageas 5.844 109.914
Agfa-Gevaert 14 2.075
Ahold 3.538 74.363
Air France - KLM 1.025 35.336
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.075
Alfen 16 25.511
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.254
Alpha Pro Tech 1 17
Alphabet Inc. 1 427
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.288
AMG 972 134.800
AMS 3 73
Amsterdam Commodities 305 6.757
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.112
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.109
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.382
Aroundtown SA 1 221
Arrowhead Research 5 9.759
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.707
ASML 1.767 112.484
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.363
Axsome Therapeutics 1 177
Azelis Group 1 69
Azerion 7 3.463